The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia

Affiliations

• ¹ Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
• ² Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
• ³ Haematology Clinic and BMT Unit, NKUA, Laiko General Hospital, Athens, Greece.
• ⁴ The Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, China.
• ⁵ Department of Hematology, S. P. Botkin City Clinical Hospital, Moscow, Russia.
• ⁶ Department of Hematology, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
• ⁷ Seoul National University Hospital, Seoul, Republic of Korea.
• ⁸ Almazov National Medical Research Centre, Saint Petersburg, Russia.
• ⁹ Genentech, South San Francisco, California, USA.
• ¹⁰ AbbVie, Inc, North Chicago, Illinois, USA.
• ¹¹ Centre Hospitalier Universitaire de Toulouse, Institut Universitaire du Cancer de Toulouse Oncopole, Université de Toulouse 3 Paul Sabatier, Toulouse, France.